NO20065544L - Urea-antagonister av P2Y1-reseptor anvendbare i behandling av trombotiske tilstander. - Google Patents
Urea-antagonister av P2Y1-reseptor anvendbare i behandling av trombotiske tilstander.Info
- Publication number
- NO20065544L NO20065544L NO20065544A NO20065544A NO20065544L NO 20065544 L NO20065544 L NO 20065544L NO 20065544 A NO20065544 A NO 20065544A NO 20065544 A NO20065544 A NO 20065544A NO 20065544 L NO20065544 L NO 20065544L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- thrombotic conditions
- receptor useful
- receptor
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer nye urinstoffer inneholdende N-aryl-eller N-heteroaryl-substituerte, heterocykliske grupper, og analoger derav, som er selektive hemmere av den humane P2Y-|-reseptor. Oppfinnelsen tilveiebringer også forskjellige farmasøytiske preparater av samme, og metoder for behandling av sykdommer som er mottagelige for modulering av P2Y-|-reseptor-aktivitet.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57028804P | 2004-05-12 | 2004-05-12 | |
US66573505P | 2005-03-28 | 2005-03-28 | |
US11/126,567 US7550499B2 (en) | 2004-05-12 | 2005-05-10 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
PCT/US2005/016525 WO2005113537A2 (en) | 2004-05-12 | 2005-05-11 | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065544L true NO20065544L (no) | 2006-12-05 |
Family
ID=35169638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065544A NO20065544L (no) | 2004-05-12 | 2006-12-01 | Urea-antagonister av P2Y1-reseptor anvendbare i behandling av trombotiske tilstander. |
Country Status (17)
Country | Link |
---|---|
US (1) | US7550499B2 (no) |
EP (1) | EP1750704B1 (no) |
JP (1) | JP4795336B2 (no) |
KR (1) | KR20070011479A (no) |
CN (2) | CN1984655B (no) |
AU (1) | AU2005245400A1 (no) |
CY (1) | CY1109487T1 (no) |
DE (1) | DE602005015577D1 (no) |
DK (1) | DK1750704T3 (no) |
ES (1) | ES2328716T3 (no) |
HR (1) | HRP20090468T1 (no) |
MX (1) | MXPA06013024A (no) |
NO (1) | NO20065544L (no) |
PL (1) | PL1750704T3 (no) |
PT (1) | PT1750704E (no) |
SI (1) | SI1750704T1 (no) |
WO (1) | WO2005113537A2 (no) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7470712B2 (en) * | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
US7388021B2 (en) * | 2004-05-12 | 2008-06-17 | Bristol Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
MX2007008434A (es) * | 2005-01-19 | 2007-07-25 | Squibb Bristol Myers Co | Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos. |
DE602006017694D1 (de) * | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
WO2007002634A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
EP1896417B1 (en) * | 2005-06-27 | 2011-03-23 | Bristol-Myers Squibb Company | Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
AU2006261828A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
WO2008023235A1 (en) * | 2006-08-25 | 2008-02-28 | Pfizer Products Inc. | Pyrazole derivatives as anti-platelet and anti-thrombotic agents |
US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
KR100858460B1 (ko) * | 2007-05-16 | 2008-09-12 | 최원진 | 장아찌의 제조방법 |
KR20130044382A (ko) * | 2010-03-01 | 2013-05-02 | 마이렉시스 인코포레이티드 | 화합물 및 그의 치료 용도 |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
WO2012177896A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
JP2014527511A (ja) | 2011-06-24 | 2014-10-16 | アムジエン・インコーポレーテツド | Trpm8拮抗剤及び治療におけるそれらの使用 |
US9096599B2 (en) | 2011-08-04 | 2015-08-04 | Intervet Inc. | Spiroindoline compounds |
CN103172543B (zh) * | 2011-12-21 | 2016-02-10 | 中国科学院上海药物研究所 | 一种脲类化合物、制备方法及其用途 |
WO2014022253A1 (en) | 2012-08-01 | 2014-02-06 | Bristol-Myers Squibb Company | Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor |
WO2014022349A1 (en) * | 2012-08-01 | 2014-02-06 | Bristol-Myers Squibb Company | 7-hydroxy-spiropipiperidine indolinyl antagonists of p2y1 receptor |
WO2014022343A1 (en) * | 2012-08-01 | 2014-02-06 | Bristol-Myers Squibb Company | 7-hydroxy-indolinyl antagonists of p2y1 receptor |
US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
CN102924442B (zh) * | 2012-11-15 | 2014-10-29 | 沈阳药科大学 | 含有噻唑环的色满类化合物及其类似物和医药用途 |
CN103012381B (zh) * | 2013-01-10 | 2015-01-07 | 山东大学 | 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用 |
CN104402875A (zh) * | 2014-12-25 | 2015-03-11 | 西安山川医药科技有限公司 | N-(2-氨基乙基)-n′-(6-取代-2-苯并噻唑基)脲及其盐类化合物的合成方法和用途 |
GB201721961D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721960D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721967D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721957D0 (en) * | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721964D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
EP4095134A1 (en) | 2021-05-25 | 2022-11-30 | UCL Business Ltd | Polycyclic compounds for the treatment of neurological indications |
EP4094762A1 (en) | 2021-05-25 | 2022-11-30 | UCL Business Ltd | Treatment of neurological indications |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3118888A (en) | 1964-01-21 | Acylated s-triazines and process for their preparation | ||
NL280954A (no) | 1961-07-14 | |||
US4179563A (en) | 1978-05-19 | 1979-12-18 | Warner-Lambert Company | 3-Aryloxy-substituted-aminopyridines and methods for their production |
US4186199A (en) | 1978-11-02 | 1980-01-29 | American Hoechst Corporation | Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines |
DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
JPS56166180A (en) | 1980-05-28 | 1981-12-21 | Chugai Pharmaceut Co Ltd | Dibenzoxazepine derivative and its preparation |
JPS56167649A (en) | 1980-05-30 | 1981-12-23 | Chugai Pharmaceut Co Ltd | Diphenyl ether derivative |
JPS5872562A (ja) * | 1981-10-23 | 1983-04-30 | Mitsubishi Chem Ind Ltd | テトラヒドロフタルイミド類 |
US4663453A (en) | 1983-05-18 | 1987-05-05 | Hoechst-Roussel Pharmaceuticals Inc. | Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity |
US4761411A (en) | 1983-05-18 | 1988-08-02 | Hoechst-Roussel Pharmaceuticals Inc. | Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses |
JPS62280847A (ja) | 1986-05-30 | 1987-12-05 | Konica Corp | 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料 |
US4840947A (en) | 1986-10-14 | 1989-06-20 | Hoechst-Roussel Pharmaceuticals, Inc. | Antiinflammatory and analgesic piperidin-4-yl-tetracyclic benzodiazepines and use thereas |
JP2577222B2 (ja) | 1987-04-10 | 1997-01-29 | 興和株式会社 | 新規な置換アニリド誘導体 |
JPH0339740A (ja) | 1989-07-06 | 1991-02-20 | Konica Corp | 転写型熱現像カラー感光材料 |
JP2951434B2 (ja) | 1991-04-18 | 1999-09-20 | 三菱製紙株式会社 | 電子写真感光体 |
NZ264063A (en) | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
JP3395285B2 (ja) | 1993-10-06 | 2003-04-07 | 日本製紙株式会社 | 感熱記録体 |
US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
DE4443641A1 (de) | 1994-12-08 | 1996-06-13 | Bayer Ag | Substituierte Carbonsäureamide |
WO1996025157A1 (en) | 1995-02-17 | 1996-08-22 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
KR19980703048A (ko) | 1995-03-20 | 1998-09-05 | 피터쥐.스트링거 | 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1h-인돌: 신규한 5-ht1f 아고니스트 |
WO1997017329A1 (fr) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant |
BR9708347A (pt) | 1996-03-25 | 1999-08-03 | Lilly Co Eli | Compostos de tetrahidorbeta-carbonila |
EP0929218A4 (en) | 1996-10-30 | 2001-05-16 | Univ North Carolina | R2Y RECEPTOR ANTAGONISTS |
US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
US6020357A (en) | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
US5858289A (en) | 1997-02-24 | 1999-01-12 | Global Consulting, Inc. | Process for preparing compressed shape of ceramic fiber |
ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
NZ503491A (en) | 1997-11-10 | 2002-08-28 | Bristol Myers Squibb Co | 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors |
EP1047691A1 (en) | 1997-12-12 | 2000-11-02 | Smithkline Beecham Plc | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
DE1042305T1 (de) | 1997-12-22 | 2001-04-19 | Bayer Ag | HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN |
AU2219599A (en) * | 1998-01-15 | 1999-08-02 | Millennium Pharmaceuticals, Inc. | Platelet adp receptor inhibitors |
US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
ES2318899T3 (es) | 1998-07-06 | 2009-05-01 | Bristol-Myers Squibb Company | Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina. |
HUP0104026A3 (en) | 1998-10-06 | 2002-06-28 | Dainippon Pharmaceutical Co | 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation |
CA2348159A1 (en) | 1998-10-20 | 2000-04-27 | Satoru Oi | Aromatic amine derivatives, their production and use |
GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
JP4820488B2 (ja) | 1999-03-12 | 2011-11-24 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症薬として有用な化合物 |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
MXPA01010292A (es) | 1999-04-15 | 2002-10-23 | Squibb Bristol Myers Co | Inhibidores ciclicos de la proteina tirosina cinasa. |
WO2000076970A2 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Serine protease inhibitors |
CO5200760A1 (es) | 1999-06-16 | 2002-09-27 | Smithkline Beecham Corp | Antagonistas del receptor de la il-8 ceptor il-8 |
JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
WO2001023358A1 (fr) | 1999-09-27 | 2001-04-05 | Sagami Chemical Research Center | Derives pyrazole, intermediaires pour la preparation de ces derives, procedes de preparation des derives et intermediaires, et herbicides dont ces derives sont le principe actif |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
ATE336492T1 (de) | 2000-01-14 | 2006-09-15 | Us Gov Health & Human Serv | Methonocarbacycloalkylanaloga von nucleosiden |
KR20020070385A (ko) | 2000-01-29 | 2002-09-06 | 주식회사 엘지씨아이 | 아릴-아미딘을 가진 팩터 Xa 억제제와 그의 유도체, 및그의 프로드럭 |
EP1257550B1 (en) * | 2000-02-04 | 2005-11-16 | Portola Pharmaceuticals, Inc. | Platelet adp receptor inhibitors |
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
KR20020084116A (ko) | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
US6586453B2 (en) | 2000-04-03 | 2003-07-01 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
JP2004517936A (ja) | 2001-01-31 | 2004-06-17 | ピーアンドジー−クレイロール・インコーポレイテッド | 酸化毛髪染色において使用する新規のカップラー |
WO2002064211A1 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
US6706711B2 (en) | 2001-04-27 | 2004-03-16 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitor |
US20040254185A1 (en) | 2001-05-08 | 2004-12-16 | Alexander Ernst | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
CA2455754A1 (en) | 2001-07-31 | 2003-02-20 | Bayer Healthcare Ag | Amine derivatives |
NZ530782A (en) | 2001-08-06 | 2005-11-25 | Pharmacia Italia S | Aminoisoxazole derivatives active as kinase inhibitors |
CH1427415H1 (de) | 2001-09-21 | 2023-12-21 | Bristol Myers Squibb Holdings Ireland | Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer |
US20050009815A1 (en) | 2001-11-27 | 2005-01-13 | Devita Robert J. | 4-Aminoquinoline compounds |
AU2002358700A1 (en) | 2001-12-26 | 2003-07-15 | Bayer Aktiengesellschaft | Urea derivatives as vr1- antagonists |
JP2003192587A (ja) | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
AU2003210969A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
DE10213228A1 (de) | 2002-03-25 | 2003-10-16 | Bayer Ag | Cyclopenten-Derivate |
MXPA04011048A (es) | 2002-05-06 | 2005-02-17 | Vertex Pharmaceutivals Inc | Tiadiazol o oxasiazoles y su uso como inhibidores de proteina cinasa jak. |
CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
DE60316297T2 (de) | 2002-08-01 | 2008-06-19 | Neurosearch A/S | Verbindungen, die zur behandlung von erkrankungen, die auf antiangiogene therapie ansprechen, nützlich sind |
NZ538513A (en) | 2002-09-05 | 2007-02-23 | Neurosearch As | Diarylurea derivatives and their use as chloride channel blockers |
EP1402888A1 (en) | 2002-09-18 | 2004-03-31 | Jerini AG | The use of substituted carbocyclic compounds as rotamases inhibitors |
US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
TWM252710U (en) | 2003-07-18 | 2004-12-11 | Huei-Chiun Shiu | Annealing equipment |
WO2005012221A1 (ja) | 2003-08-04 | 2005-02-10 | Ono Pharmaceutical Co., Ltd. | ジフェニルエーテル化合物、その製造方法および用途 |
US20050256161A1 (en) | 2003-08-13 | 2005-11-17 | Tempest Paul A | Melanin concentrating hormone receptor antagonists |
JP4771468B2 (ja) | 2003-12-26 | 2011-09-14 | 正敏 萩原 | Sr蛋白質のリン酸化制御方法、および、sr蛋白質の活性制御剤を有効成分とする抗ウイルス剤 |
US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
TW200530236A (en) * | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
US7388021B2 (en) | 2004-05-12 | 2008-06-17 | Bristol Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
MX2007008434A (es) | 2005-01-19 | 2007-07-25 | Squibb Bristol Myers Co | Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos. |
DE602006017694D1 (de) | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
AU2006261828A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
WO2007002634A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
EP1896417B1 (en) | 2005-06-27 | 2011-03-23 | Bristol-Myers Squibb Company | Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
-
2005
- 2005-05-10 US US11/126,567 patent/US7550499B2/en active Active
- 2005-05-11 PL PL05779448T patent/PL1750704T3/pl unknown
- 2005-05-11 DK DK05779448T patent/DK1750704T3/da active
- 2005-05-11 JP JP2007513323A patent/JP4795336B2/ja not_active Expired - Fee Related
- 2005-05-11 KR KR1020067023615A patent/KR20070011479A/ko not_active Application Discontinuation
- 2005-05-11 PT PT05779448T patent/PT1750704E/pt unknown
- 2005-05-11 CN CN2005800231306A patent/CN1984655B/zh not_active Expired - Fee Related
- 2005-05-11 DE DE602005015577T patent/DE602005015577D1/de active Active
- 2005-05-11 SI SI200530770T patent/SI1750704T1/sl unknown
- 2005-05-11 ES ES05779448T patent/ES2328716T3/es active Active
- 2005-05-11 WO PCT/US2005/016525 patent/WO2005113537A2/en active Application Filing
- 2005-05-11 CN CNA2005800236206A patent/CN1984892A/zh active Pending
- 2005-05-11 EP EP05779448A patent/EP1750704B1/en active Active
- 2005-05-11 AU AU2005245400A patent/AU2005245400A1/en not_active Abandoned
- 2005-05-11 MX MXPA06013024A patent/MXPA06013024A/es active IP Right Grant
-
2006
- 2006-12-01 NO NO20065544A patent/NO20065544L/no not_active Application Discontinuation
-
2009
- 2009-09-03 HR HR20090468T patent/HRP20090468T1/hr unknown
- 2009-10-13 CY CY20091101048T patent/CY1109487T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK1750704T3 (da) | 2009-11-02 |
HRP20090468T1 (hr) | 2009-09-30 |
AU2005245400A1 (en) | 2005-12-01 |
EP1750704A2 (en) | 2007-02-14 |
PT1750704E (pt) | 2009-10-06 |
PL1750704T3 (pl) | 2010-01-29 |
DE602005015577D1 (de) | 2009-09-03 |
CN1984892A (zh) | 2007-06-20 |
CN1984655A (zh) | 2007-06-20 |
KR20070011479A (ko) | 2007-01-24 |
EP1750704B1 (en) | 2009-07-22 |
WO2005113537A2 (en) | 2005-12-01 |
US7550499B2 (en) | 2009-06-23 |
MXPA06013024A (es) | 2006-12-20 |
ES2328716T3 (es) | 2009-11-17 |
JP4795336B2 (ja) | 2011-10-19 |
SI1750704T1 (sl) | 2009-12-31 |
CY1109487T1 (el) | 2012-05-23 |
CN1984655B (zh) | 2011-11-30 |
US20050261244A1 (en) | 2005-11-24 |
JP2007537273A (ja) | 2007-12-20 |
WO2005113537A3 (en) | 2005-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20065544L (no) | Urea-antagonister av P2Y1-reseptor anvendbare i behandling av trombotiske tilstander. | |
NO20065534L (no) | Ureaantagonister av P2Y1-reseptor anvendbare i behandling av trombotiske tilstander. | |
NO20063191L (no) | Aminobenzazoler som P2Y1-reseptorinhibitorer | |
NO20073665L (no) | 2-fenoksy-N-(1,3,4-tiadizol-2-yl) Pyridin-3-aminderivater og beslektede forbindelser som P2Y1 reseptor inhibitorer for behandling av tromboemboliforstyrrelser | |
ATE485269T1 (de) | C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden | |
NO20076424L (no) | N-koblete heterocykliske antagonister av P2Y1 reseptoren nyttige for behandling av tromboseforstyrrelser | |
ATE502924T1 (de) | Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden | |
EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
ATE487484T1 (de) | Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür | |
ATE469897T1 (de) | Indazolcarbonsäureamidverbindungen | |
EA200800564A1 (ru) | Производные ксантина как селективные агонисты нм74а | |
EA200900211A1 (ru) | Замещенные производные имидазолона, их получение и применение | |
EA200700117A1 (ru) | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов | |
UA111579C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ | |
EA200700142A1 (ru) | Замещенные гетероциклом циклические производные мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы | |
NO20062677L (no) | Benzyleteraminforbindelser anvendbare som CCR-5-antagonister | |
UA83311C2 (en) | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | |
NO20052272L (no) | CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom | |
BRPI0418939A (pt) | derivados de nicotinamida e sua utilização como agentes terapêuticos | |
BRPI0516883A (pt) | compostos e métodos para modulação da atividade de trombopoietina | |
IL192557A (en) | Imidazole derivatives are conserved and used as ptpase inhibitors | |
CY1109808T1 (el) | Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α | |
DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |